• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.

作者信息

Schavgoulidze Anaïs, Perrot Aurore, Cazaubiel Titouan, Leleu Xavier, Montes Lydia, Jacquet Caroline, Belhadj Karim, Brechignac Sabine, Frenzel Laurent, Chalopin Thomas, Rey Philippe, Schiano de Collela Jean-Marc, Dib Mamoun, Caillot Denis, Macro Margaret, Fontan Jean, Buisson Laure, Pavageau Luka, Roussel Murielle, Manier Salomon, Mohty Mohamad, Martinet Ludovic, Avet-Loiseau Hervé, Corre Jill

机构信息

Unit for Genomics in Myeloma, University Hospital IUCT-Oncopole, Toulouse, France.

Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Toulouse III-Paul Sabatier (UPS), Toulouse, France.

出版信息

Blood Cancer J. 2023 Oct 26;13(1):160. doi: 10.1038/s41408-023-00933-4.

DOI:10.1038/s41408-023-00933-4
PMID:37880285
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10600097/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/10600097/c88795ddc737/41408_2023_933_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/10600097/a8acf899382b/41408_2023_933_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/10600097/c88795ddc737/41408_2023_933_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/10600097/a8acf899382b/41408_2023_933_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/10600097/c88795ddc737/41408_2023_933_Fig2_HTML.jpg

相似文献

1
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.根据其他基因损伤的存在情况，探讨14号与16号染色体易位t(14;16)在多发性骨髓瘤中的预后影响。
Blood Cancer J. 2023 Oct 26;13(1):160. doi: 10.1038/s41408-023-00933-4.
2
The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.多发性骨髓瘤细胞系KMS12中的t(11;14)(q13;q32)，其11q13断点位于细胞周期蛋白D1基因着丝粒方向330 kb处。
Blood. 1997 Jan 1;89(1):349-50.
3
Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.一名患有t(4;14)易位多发性骨髓瘤患者的自发缓解
J Clin Oncol. 2009 Nov 20;27(33):e194-7. doi: 10.1200/JCO.2009.22.0392. Epub 2009 Oct 5.
4
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.浆细胞异常增生中缺失 13 获得的时间取决于遗传背景。
Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064.
5
[Multicolor spectral karyotyping (SKY) and its application to the cytogenetic diagnosis of multiple myeloma].[多色光谱核型分析（SKY）及其在多发性骨髓瘤细胞遗传学诊断中的应用]
Sangre (Barc). 1999 Aug;44(4):301-4.
6
Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.伴有IGH/MYC和IGH/CCND1易位的双打击骨髓瘤。
Ann Hematol. 2013 Aug;92(8):1129-31. doi: 10.1007/s00277-012-1668-y. Epub 2013 Jan 10.
7
MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.MMSET基因中的MB4-2断点与17p缺失相结合，定义了一组预后极差的t(4;14)多发性骨髓瘤。
Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23.
8
[Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].[多发性骨髓瘤中的基因异常：在肿瘤发生中的作用及对生存的影响]
Rev Med Interne. 2007 Oct;28(10):677-81. doi: 10.1016/j.revmed.2007.04.013. Epub 2007 May 25.
9
Deciding on the therapy of multiple myeloma using genetic risk stratification.利用基因风险分层来决定多发性骨髓瘤的治疗方案。
Leuk Lymphoma. 2011 Feb;52(2):157-8. doi: 10.3109/10428194.2010.542601. Epub 2011 Jan 24.
10
Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).硼替佐米联合地塞米松治疗一名患有t(8; 14)的年轻多发性骨髓瘤患者。
Leuk Res. 2009 Apr;33(4):584-6. doi: 10.1016/j.leukres.2008.08.013. Epub 2008 Sep 30.

引用本文的文献

1
Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma.多发性骨髓瘤生存预测的细胞遗传学双打击模型的建立
Cancers (Basel). 2025 Aug 20;17(16):2703. doi: 10.3390/cancers17162703.
2
Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.在多种涉及免疫球蛋白重链（IgH）细胞遗传学异常的高危分层中，应对多发性骨髓瘤中IgH细胞遗传学异常的预后复杂性
Cancer Med. 2025 Sep;14(17):e71152. doi: 10.1002/cam4.71152.
3
Risk factors for multiple myeloma and its precursor diseases.

本文引用的文献

1
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.1p32 双等位基因缺失定义为超高危骨髓瘤，但单等位基因 del(1p32) 仍然是一个强有力的预后因素。
Blood. 2023 Mar 16;141(11):1308-1315. doi: 10.1182/blood.2022017863.
2
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.多发性骨髓瘤的风险分层治疗展望。
Blood Cancer Discov. 2022 Jul 6;3(4):273-284. doi: 10.1158/2643-3230.BCD-21-0205.
3
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
多发性骨髓瘤及其前驱疾病的危险因素。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025 Apr 28;50(4):560-572. doi: 10.11817/j.issn.1672-7347.2025.240594.
4
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.SWIFT-seq技术能够对多发性骨髓瘤及其前驱病变中的循环肿瘤细胞进行全面的单细胞转录组分析。
Nat Cancer. 2025 Aug 8. doi: 10.1038/s43018-025-01006-0.
5
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group.多发性骨髓瘤风险分层的细胞遗传学结果检测与报告指南：癌症基因组学联盟浆细胞肿瘤工作组报告
Blood Cancer J. 2025 Jun 18;15(1):86. doi: 10.1038/s41408-025-01286-w.
6
A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma.一种用于新诊断多发性骨髓瘤患者的真实世界国际分期系统（RW-ISS）。
Blood Cancer J. 2025 Apr 7;15(1):59. doi: 10.1038/s41408-025-01268-y.
7
A rare case of multiple myeloma with double translocations: t(11;14) and t(14;16).一例罕见的具有双重易位[t(11;14)和t(14;16)]的多发性骨髓瘤病例。
J Hematop. 2025 Mar 27;18(1):11. doi: 10.1007/s12308-025-00626-w.
8
Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications.单细胞分析对多发性骨髓瘤的见解：克隆进化、微环境、治疗逃逸及临床意义
Cancers (Basel). 2025 Feb 14;17(4):653. doi: 10.3390/cancers17040653.
9
[Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].19例新诊断的伴t(14;16)的多发性骨髓瘤患者的预后分析
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):944-950. doi: 10.3760/cma.j.cn121090-20240814-00303.
10
A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs.新药时代新诊断多发性骨髓瘤的一种新的预后评分系统。
Front Med (Lausanne). 2024 Oct 22;11:1473034. doi: 10.3389/fmed.2024.1473034. eCollection 2024.
修订版国际分期系统（R2-ISS）在多发性骨髓瘤整体生存中的应用：Harmony 项目下欧洲骨髓瘤网络（EMN）的报告。
J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
4
Multiple myeloma current treatment algorithms.多发性骨髓瘤现行治疗方案。
Blood Cancer J. 2020 Sep 28;10(9):94. doi: 10.1038/s41408-020-00359-2.
5
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.多发性骨髓瘤中的全基因组体细胞改变揭示了预后较好的一类患者。
J Clin Oncol. 2020 Sep 20;38(27):3107-3118. doi: 10.1200/JCO.20.00461. Epub 2020 Jul 20.
6
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.新型药物时代携带t(14;16)的多发性骨髓瘤患者的临床特征与生存情况
Blood Cancer J. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4.
7
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.一项包含 223 例多发性骨髓瘤伴 t(14;16)患者的多中心回顾性研究。
Am J Hematol. 2020 May;95(5):503-509. doi: 10.1002/ajh.25758. Epub 2020 Feb 29.
8
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.多发性骨髓瘤患者细胞遗传学预后指数的建立与验证：对生存的预测作用。
J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.
9
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.鉴定新的突变驱动因素揭示了多发性骨髓瘤中的致癌基因依赖性。
Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8.
10
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.MAF蛋白介导多发性骨髓瘤对蛋白酶体抑制疗法的天然抗性。
Blood. 2016 Dec 22;128(25):2919-2930. doi: 10.1182/blood-2016-03-706077. Epub 2016 Oct 28.